Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Natera Inc

Healthcare US NTRA

198.95USD
-6.27(3.06%)

Last update at 2026-03-10T20:00:00Z

Day Range

198.45207.08
LowHigh

52 Week Range

36.90110.66
LowHigh

Fundamentals

  • Previous Close 205.22
  • Market Cap13499.73M
  • Volume815089
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-358.57501M
  • Revenue TTM1208.56M
  • Revenue Per Share TTM10.31
  • Gross Profit TTM 363.97M
  • Diluted EPS TTM-3.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -546.82100M -471.09800M -229.64500M -122.82800M -127.83300M
Minority interest - - - - -
Net income -547.79900M -471.71600M -229.74300M -124.82700M -128.15400M
Selling general administrative 588.59M 511.03M 303.63M 206.18M 154.87M
Selling and marketing expenses - - - - -
Gross profit 363.97M 307.07M 187.38M 126.86M 91.60M
Reconciled depreciation 16.70M 11.25M 8.61M 7.73M 7.50M
Ebit -541.04000M -468.17400M -216.27700M -130.67500M -124.85800M
Ebitda -537.50200M -462.79300M -208.71500M -126.52300M -117.35700M
Depreciation and amortization 3.54M 5.38M 7.56M 4.15M 7.50M
Non operating income net other - - -5.84800M - -
Operating income -541.04000M -468.17400M -216.27700M -130.67500M -114.62800M
Other operating expenses 1361.26M 1093.66M 607.28M 433.00M 372.28M
Interest expense 9.32M 8.30M 15.08M 10.69M 10.48M
Tax provision 0.98M 0.62M 0.10M 2.00M 0.32M
Interest income 3.54M 5.38M 7.56M 4.15M 2.73M
Net interest income -5.78100M -8.30500M -7.52000M -6.54100M -10.47600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.98M 0.62M 0.10M 2.00M 0.32M
Total revenue 820.22M 625.49M 391.00M 302.33M 257.65M
Total operating expenses 905.01M 775.24M 403.66M 257.53M 206.23M
Cost of revenue 456.26M 318.42M 203.62M 175.47M 166.06M
Total other income expense net -5.78100M -2.92400M -13.36800M 7.85M -2.72900M
Discontinued operations - - - - -
Net income from continuing ops -547.79900M -471.71600M -229.74300M -124.82700M -128.15400M
Net income applicable to common shares -547.79900M -471.71600M -229.74300M -124.82700M -128.15400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1457.12M 1394.47M 1236.49M 932.15M 582.66M
Intangible assets - - - - 1.20M
Earning assets - - - - -
Other current assets 60.52M 33.63M 29.64M 26.61M 16.38M
Total liab 691.80M 688.73M 583.18M 445.92M 303.94M
Total stockholder equity 765.33M 705.74M 653.30M 486.24M 278.71M
Deferred long term liab - - - - 1.10M
Other current liab 183.64M 188.22M 134.29M 90.78M 65.13M
Common stock 0.01M 0.01M 0.01000M 0.00900M 0.00800M
Capital stock 0.01M 0.01M 0.01000M 0.00900M 0.00800M
Retained earnings -2377.43600M -1942.63500M -1394.83600M -929.31800M -699.17100M
Other liab - 20.00M 22.80M 23.12M 24.12M
Good will - - - - -
Other assets - 18.33M 18.82M 36.14M 12.48M
Cash 642.10M 466.00M 84.39M 48.67M 61.93M
Cash and equivalents - - - - -
Total current liabilities 307.27M 310.50M 218.96M 199.05M 179.87M
Current deferred revenue 16.61M 10.78M 7.40M 50.12M 56.02M
Net debt -200.10200M -27.42500M 307.10M 225.12M 88.15M
Short term debt 92.02M 80.35M 50.05M 50.05M 50.12M
Short long term debt 80.40M 80.35M 50.05M 50.05M 50.12M
Short long term debt total 441.99M 438.58M 391.48M 273.79M 150.08M
Other stockholder equity 3145.84M 2664.73M 2050.42M 1411.29M 976.96M
Property plant equipment - 92.45M 65.52M 33.35M 23.28M
Total current assets 1258.55M 1211.82M 1093.14M 862.66M 523.17M
Long term investments - - - - -
Net tangible assets - 705.74M 653.30M 486.24M 278.71M
Short term investments 236.88M 432.30M 829.90M 688.61M 379.06M
Net receivables 278.29M 244.38M 122.07M 78.56M 53.35M
Long term debt 282.94M 281.65M 280.39M 202.49M 73.66M
Inventory 40.76M 35.41M 26.91M 20.03M 12.39M
Accounts payable 15.00M 31.15M 27.21M 8.10M 8.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.08500M -16.36200M -2.28700M 4.26M 0.92M
Additional paid in capital - - - - -
Common stock total equity - 0.01M 0.01000M 0.00900M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - -1942.63500M -1394.83600M -929.31800M -699.17100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.40M 18.33M 18.82M 14.74M 12.48M
Deferred long term asset charges - - - - -
Non current assets total 198.58M 182.66M 143.35M 69.49M 59.49M
Capital lease obligations 78.65M 76.58M 66.79M 28.55M 32.04M
Long term debt total - 281.65M 280.39M 202.49M 73.66M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 378.04M -155.60500M -311.85700M -271.06000M -1.28100M
Change to liabilities 56.18M 62.47M 24.52M 6.07M 47.80M
Total cashflows from investing activities 330.34M -205.19300M -331.46100M -266.35300M -5.16100M
Net borrowings 30.00M 30.00M 199.56M 199.56M 199.56M
Total cash from financing activities 482.64M 576.19M 500.85M 340.77M 113.72M
Change to operating activities 40.14M 29.77M 1.19M -10.72000M 3.60M
Net income -547.79900M -471.71600M -229.74300M -124.82700M -128.15400M
Change in cash 381.48M 35.76M -13.12600M 10.98M 37.98M
Begin period cash flow 84.61M 48.85M 61.98M 51.00M 13.02M
End period cash flow 466.09M 84.61M 48.85M 61.98M 51.00M
Total cash from operating activities -431.50100M -335.23600M -182.51200M -63.44400M -70.58100M
Issuance of capital stock 433.19M 550.82M 270.65M 323.41M 96.78M
Depreciation 16.70M 11.25M 8.61M 7.73M 7.50M
Other cashflows from investing activities - -8.55800M - 9.68M -1.28100M
Dividends paid - - -7.11400M - -
Change to inventory -8.25700M -7.50600M -7.47400M 0.92M -4.90000M
Change to account receivables -124.08100M -43.35300M -25.83100M 2.42M -18.09300M
Sale purchase of stock 13.04M 13.55M 7.11M 4.32M 3.62M
Other cashflows from financing activities 36.41M 11.82M 308.95M 13.04M 13.33M
Change to netincome 164.11M 151.24M 56.96M 17.30M 20.11M
Capital expenditures 47.70M 41.03M 19.60M 4.97M 3.88M
Change receivables -124.08100M -43.35300M -25.83100M 2.42M -18.09300M
Cash flows other operating 5.55M -46.66700M -15.45900M 25.54M 4.52M
Exchange rate changes - - - - -
Cash and cash equivalents changes 381.48M 35.76M -13.12600M 10.98M 37.98M
Change in working capital -84.68000M -46.07300M -39.13000M 27.20M 27.16M
Stock based compensation 152.38M 115.22M 50.17M 28.62M 14.20M
Other non cash items 31.89M 48.48M 14.72M 8.47M 2.83M
Free cash flow -479.19800M -376.26600M -202.11600M -68.41200M -74.46100M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NTRA
Natera Inc		 -6.27 3.06% 198.95 - - 10.54 14.90 10.13 -27.5765
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Natera Inc

13011 McCallen Pass, Austin, TX, United States, 78753

Key Executives

Name Title Year Born
Dr. Matthew Rabinowitz Ph.D. Co-Founder & Exec. Chairman 1973
Mr. Steven Leonard Chapman CEO, Pres & Director 1979
Mr. Michael B. Brophy M.B.A. Chief Financial Officer 1980
Mr. Robert A. Schueren Chief Operating Officer 1962
Mr. Daniel Rabinowitz L.L.M., LL.M. Sec. & Chief Legal Officer 1969
Mr. Jonathan Sheena M.Eng. Co-Founder & Director 1973
Ms. Olesya A. Anisimova CPA Chief Accounting Officer NA
Mr. Rishi Kacker Chief Technology Officer NA
Mr. Eric A. Evans Chief Scientific Officer NA
Mr. Phil Grinnell VP of Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.